Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lomitapide
Drug ID BADD_D01311
Description Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Indications and Usage Used in homozygous familial hypercholesterolemia (HoFH) patients to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C).
Marketing Status Prescription
ATC Code C10AX12
DrugBank ID DB08827
KEGG ID D09637
MeSH ID C473731
PubChem ID 9853053
TTD Drug ID D0H8VY
NDC Product Code Not Available
Synonyms BMS201038 | BMS-201038 | BMS 201038 | lomitapide | Juxtapid | AEGR 733 | AEGR733 | AEGR-733
Chemical Information
Molecular Formula C39H37F6N3O2
CAS Registry Number 182431-12-5
SMILES C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C (=O)NCC(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
TeratogenicityCytochrome P450 3A4P08684T3784826240881
TeratogenicityATP-binding cassette subfamily B member 1AQ9JK64Not Available26240881
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Stress19.06.02.0040.000181%Not Available
Throat irritation22.02.05.013; 07.05.03.0040.000121%Not Available
Throat tightness22.02.05.015; 19.01.02.0050.000121%Not Available
Toothache07.09.06.0010.000302%
Trigeminal neuralgia17.04.08.0010.000181%Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.0090.000181%
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.0040.000724%
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.003--
Viral infection11.05.04.0010.000181%Not Available
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.0030.002414%
Weight decreased13.15.01.0050.016655%
Weight increased13.15.01.0060.002896%
White blood cell count decreased13.01.06.012--
White blood cell count increased13.01.06.013--Not Available
Xanthoma23.03.03.047; 14.08.04.0100.000181%Not Available
Mobility decreased17.02.05.018; 15.03.01.003; 08.01.03.0300.000181%Not Available
Musculoskeletal disorder15.03.01.004--Not Available
Peripheral swelling02.05.04.015; 08.01.03.053--Not Available
Weight fluctuation14.03.02.0020.000483%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.000121%
Lower gastrointestinal haemorrhage07.12.02.007; 24.07.02.030--
Neutrophil percentage increased13.01.06.040--Not Available
Lymphatic disorder01.09.01.003--Not Available
Aerophagia07.01.04.004--Not Available
Epigastric discomfort07.01.02.004--Not Available
Musculoskeletal discomfort15.03.04.0010.000181%Not Available
The 7th Page    First    Pre   7 8 9    Next   Last    Total 9 Pages